Shionogi & Co.,Ltd. (4507) Stock Price

Shionogi Pharmaceutical Co., Ltd. is primarily engaged in the research and development, procurement, manufacturing, and sales of prescription pharmaceuticals. This business operates as a single segment, with activities spanning the entire lifecycle of pharmaceutical products. Specifically, the company handles new drug development, market launch, and product promotion.

The company's group includes subsidiaries such as Shionogi Pharma Co., Ltd. and Shionogi Healthcare Co., Ltd. These affiliated companies play important roles across research and development, manufacturing, and sales stages to address various needs in the pharmaceutical industry. The company also maintains overseas operations including Shionogi Inc. and Qpex Biopharma, Inc., advancing its global expansion.

Shionogi Pharmaceutical actively pursues pharmaceutical research and development. The company focuses particularly on developing new drugs for infectious diseases and central nervous system disorders, thereby contributing to medical advancement. Additionally, the company collaborates with research institutions such as Shionogi Techno Advanced Research Co., Ltd. to promote new drug development utilizing cutting-edge technology.

Shionogi Pharmaceutical has set a vision for 2030: "Creating the future of healthcare through new platforms." To realize this vision, the company is transforming from a "drug discovery-focused pharmaceutical company" centered on prescription medicines into a "Healthcare as a Service (HaaS) company" that provides healthcare services. Through this transformation, the company aims to comprehensively address challenges faced by patients and society while delivering new value.

In 2020, Shionogi announced its medium-term management plan "Shionogi Transformation Strategy 2030 (STS2030)" to advance toward realizing its 2030 vision. In 2023, the company updated STS2030 based on changes in the external environment and results from the previous three years, establishing "STS2030 Revision." This plan designates fiscal years 2023 through 2025 as "STS Phase2," aiming to accelerate growth through transformation.

STS2030 Revision identifies three pillars of growth strategy: "Further growth of the HIV business," "Acute respiratory infection business," and "Expansion of new products and new businesses." In the HIV business particularly, the company is advancing development of long-acting formulations to drive sustained growth. In the acute respiratory infection business, the company is developing treatments for COVID-19 and influenza while working to establish a sustainable business model.

Additionally, Shionogi has positioned freedom from the threat of infectious diseases as a key priority and is working to address healthcare challenges in the infectious disease field. This includes developing COVID-19 treatments and creating universal vaccines to address next-generation infectious diseases. The company is also advancing development of new antibiotics and improving treatment access in low- and middle-income countries as part of its response to antimicrobial resistance (AMR).